Comparable Safety Profile: FASLODEX 500 mg vs FASLODEX 250 mg1
The CONFIRM study results showed a comparable safety profile when comparing FASLODEX 500 mg to FASLODEX 250 mg.
Most commonly reported adverse events (≥5% in either treatment group)
View the data for efficacy
- 2 patients (0.6%) receiving FASLODEX 500 mg and 3 patients (0.8%) receiving 250 mg discontinued due to drug-related adverse events5
- Patients received the same number of injections1
- FASLODEX 500-mg arm received 2 x 250-mg injections on days 1, 15, and 29 and once monthly thereafter
- FASLODEX 250-mg arm received 1 x 250-mg injection plus one placebo injection on days 1, 15 (2 placebo injections only), and 29 and once monthly thereafter
- Increased hepatic enzymes (AST, ALT, ALP) occurred in >15% of FASLODEX users and were non dose-dependent
FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease
progression following antiestrogen therapy.
IMPORTANT SAFETY INFORMATION:
Click Here for Additional Safety Information
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to
any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.
OnCue - News for
Regularly updated articles cover a range of topics including treatment information, oncology conferences details, and patient resources.
AZ ProCare Webcasts
Hear from disease-state experts about the treatment and management of HR+ metastatic breast cancer through live and archived Webcasts.